MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - pharmaceuticals
- TTK HEALTHCARE - IPCA LABS
TTK HEALTHCARE vs IPCA LABS - Comparison Results
Current Valuations
| TTK HEALTHCARE | IPCA LABS | TTK HEALTHCARE/ IPCA LABS |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 19.1 | 29.7 | 64.3% | View Chart |
| P/BV | x | 4.9 | 4.4 | 111.7% | View Chart |
| Dividend Yield | % | 0.6 | 0.1 | 554.4% |
Financials
 TTK HEALTHCARE  IPCA LABS |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| TTK HEALTHCARE Mar-14 |
IPCA LABS Mar-18 |
TTK HEALTHCARE/ IPCA LABS |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 663 | 695 | 95.4% | |
| Low | Rs | 399 | 400 | 99.8% | |
| Sales per share (Unadj.) | Rs | 535.6 | 260.2 | 205.9% | |
| Earnings per share (Unadj.) | Rs | 15.9 | 19.0 | 84.1% | |
| Cash flow per share (Unadj.) | Rs | 20.0 | 33.1 | 60.6% | |
| Dividends per share (Unadj.) | Rs | 4.00 | 1.00 | 400.0% | |
| Dividend yield (eoy) | % | 0.8 | 0.2 | 412.4% | |
| Book value per share (Unadj.) | Rs | 137.6 | 213.0 | 64.6% | |
| Shares outstanding (eoy) | m | 7.77 | 126.20 | 6.2% | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 1.0 | 2.1 | 47.1% | |
| Avg P/E ratio | x | 33.3 | 28.9 | 115.4% | |
| P/CF ratio (eoy) | x | 26.5 | 16.6 | 160.1% | |
| Price / Book Value ratio | x | 3.9 | 2.6 | 150.1% | |
| Dividend payout | % | 25.1 | 5.3 | 475.9% | |
| Avg Mkt Cap | Rs m | 4,127 | 69,120 | 6.0% | |
| No. of employees | `000 | 1.7 | 13.3 | 12.9% | |
| Total wages/salary | Rs m | 607 | 7,359 | 8.2% | |
| Avg. sales/employee | Rs Th | 2,436.7 | 2,477.4 | 98.4% | |
| Avg. wages/employee | Rs Th | 355.2 | 555.2 | 64.0% | |
| Avg. net profit/employee | Rs Th | 72.5 | 180.6 | 40.2% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 4,162 | 32,836 | 12.7% | |
| Other income | Rs m | 61 | 418 | 14.6% | |
| Total revenues | Rs m | 4,223 | 33,254 | 12.7% | |
| Gross profit | Rs m | 197 | 4,505 | 4.4% | |
| Depreciation | Rs m | 32 | 1,777 | 1.8% | |
| Interest | Rs m | 30 | 240 | 12.4% | |
| Profit before tax | Rs m | 197 | 2,905 | 6.8% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 73 | 511 | 14.2% | |
| Profit after tax | Rs m | 124 | 2,394 | 5.2% | |
| Gross profit margin | % | 4.7 | 13.7 | 34.5% | |
| Effective tax rate | % | 37.0 | 17.6 | 210.4% | |
| Net profit margin | % | 3.0 | 7.3 | 40.8% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 1,629 | 19,455 | 8.4% | |
| Current liabilities | Rs m | 1,058 | 10,076 | 10.5% | |
| Net working cap to sales | % | 13.7 | 28.6 | 48.0% | |
| Current ratio | x | 1.5 | 1.9 | 79.7% | |
| Inventory Days | Days | 30 | 98 | 30.4% | |
| Debtors Days | Days | 34 | 67 | 50.2% | |
| Net fixed assets | Rs m | 556 | 20,260 | 2.7% | |
| Share capital | Rs m | 78 | 252 | 30.8% | |
| "Free" reserves | Rs m | 878 | 26,633 | 3.3% | |
| Net worth | Rs m | 1,069 | 26,886 | 4.0% | |
| Long term debt | Rs m | 159 | 2,340 | 6.8% | |
| Total assets | Rs m | 2,399 | 41,173 | 5.8% | |
| Interest coverage | x | 7.6 | 13.1 | 57.9% | |
| Debt to equity ratio | x | 0.1 | 0.1 | 170.5% | |
| Sales to assets ratio | x | 1.7 | 0.8 | 217.5% | |
| Return on assets | % | 6.4 | 6.4 | 100.2% | |
| Return on equity | % | 11.6 | 8.9 | 130.1% | |
| Return on capital | % | 18.5 | 10.8 | 171.5% | |
| Exports to sales | % | 0.8 | 47.6 | 1.7% | |
| Imports to sales | % | 1.4 | 14.9 | 9.4% | |
| Exports (fob) | Rs m | 33 | 15,642 | 0.2% | |
| Imports (cif) | Rs m | 58 | 4,884 | 1.2% | |
| Fx inflow | Rs m | 33 | 15,642 | 0.2% | |
| Fx outflow | Rs m | 63 | 4,884 | 1.3% | |
| Net fx | Rs m | -30 | 10,759 | -0.3% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 127 | 3,411 | 3.7% | |
| From Investments | Rs m | -146 | -1,354 | 10.8% | |
| From Financial Activity | Rs m | 22 | -1,304 | -1.7% | |
| Net Cashflow | Rs m | 3 | 753 | 0.3% | |
Share Holding
| Indian Promoters | % | 65.4 | 45.9 | 142.5% | |
| Foreign collaborators | % | 0.0 | 0.0 | - | |
| Indian inst/Mut Fund | % | 3.7 | 11.4 | 32.5% | |
| FIIs | % | 5.2 | 25.3 | 20.6% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 25.8 | 17.4 | 148.3% | |
| Shareholders | 12,723 | 36,892 | 34.5% | ||
| Pledged promoter(s) holding | % | 0.0 | 2.1 | - |
Compare TTK HEALTHCARE With: DR. DATSONS LABS STRIDES PHARMA SCIENCE J.B.CHEMICALS JUBILANT LIFE SCIENCES BIOCON
Compare TTK HEALTHCARE With: ACTAVIS (US) MYLAN (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
|
| |
Today's Market
Indian Indices End Marginally Higher, Oil Prices, and Top Cues in Focus Today(Pre-Open)
Indian share markets witnessed volatility during closing hours yesterday and ended their day marginally higher.
Related Views on News
IPCA LABS Announces Quarterly Results (3QFY19); Net Profit Up 51.7% (Quarterly Result Update)
Feb 14, 2019 | Updated on Feb 14, 2019For the quarter ended December 2018, IPCA LABS has posted a net profit of Rs 2 bn (up 51.7% YoY). Sales on the other hand came in at Rs 9 bn (up 10.3% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.
TTK HEALTHCARE Announces Quarterly Results (3QFY19); Net Profit Down 60.1% (Quarterly Result Update)
Feb 1, 2019 | Updated on Feb 1, 2019For the quarter ended December 2018, TTK HEALTHCARE has posted a net profit of Rs 49 m (down 60.1% YoY). Sales on the other hand came in at Rs 1 bn (up 2.1% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.
IPCA LABS Announces Quarterly Results (2QFY19); Net Profit Up 24.1% (Quarterly Result Update)
Nov 15, 2018 | Updated on Nov 15, 2018For the quarter ended September 2018, IPCA LABS has posted a net profit of Rs 1 bn (up 24.1% YoY). Sales on the other hand came in at Rs 10 bn (up 15.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.
TTK HEALTHCARE Announces Quarterly Results (2QFY19); Net Profit Down 15.3% (Quarterly Result Update)
Nov 12, 2018 | Updated on Nov 12, 2018For the quarter ended September 2018, TTK HEALTHCARE has posted a net profit of Rs 67 m (down 15.3% YoY). Sales on the other hand came in at Rs 2 bn (up 16.3% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.
IPCA LABS Announces Quarterly Results (1QFY19); Net Profit Down 423.6% (Quarterly Result Update)
Aug 13, 2018 | Updated on Aug 13, 2018For the quarter ended June 2018, IPCA LABS has posted a net profit of Rs 655 m (down 423.6% YoY). Sales on the other hand came in at Rs 9 bn (up 19.8% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.
More Views on NewsMost Popular
5 Fundamentally Strong Stocks to Pick for Trading Today(Profit Hunter)
Mar 15, 20195 fundamentally strong stocks one could buy to trade in this market right now. Make sure you grab the chance this strongly rallying market offers.
Elections Don't Matter!(The Honest Truth)
Mar 13, 2019Ajit Dayal shows us why from the point of view of the Indian economy, elections don't matter.
Two Growth Stocks that Doubled in a Little Over 12 Months!(The 5 Minute Wrapup)
Mar 13, 2019The elements that fueled profit growth for these two companies led to a surge in their stock prices.
My Top 3 Defence Stocks to Buy Now(The 5 Minute Wrapup)
Mar 19, 2019The urgency to privatise India's defence sector to make India self-reliant was never as strong as it is today.
Sensex Nearing All-Time Highs: Stocks to Buy in this Rally(Profit Hunter)
Mar 14, 2019The BSE Sensex is heating up. In just a few days, the benchmark index is up 3%. Is this rally sustainable? Richa finds out...
More|
| |
TTK HEALTHCARE SHARE PRICE
Mar 20, 2019 (Close)
TRACK TTK HEALTHCARE
- Track your investment in TTK HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON TTK HEALTHCARE
TTK HEALTHCARE 8-QTR ANALYSIS
COMPARE TTK HEALTHCARE WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.